Dissemination: The fatal risk for a missed diagnosis of Strongyloides stercoralis infection

Journal of Infection

Volumn 55, Issue 3, 2007, Pages 284-285

  Boscolo, Marina ^a   Bisoffi, Zeno ^a  

^a SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; IVERMECTIN;

BACTERIUM CULTURE; DEATH; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIA; ERADICATION THERAPY; FECES ANALYSIS; GOLD STANDARD; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; LETTER; MEDICAL LITERATURE; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEROLOGY; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, HELMINTH; ANTIPARASITIC AGENTS; DIAGNOSIS, DIFFERENTIAL; FECES; HUMANS; IVERMECTIN; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; TIME FACTORS;

EID: 34547839186     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2007.01.009     Document Type: Letter

References (10)

1. Fardet L., Genereau T., Poirot J.L., Guidet B., Kettaneh A., and Cabane J. Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review. J Infect 54 (2007) 18-27
2. Siddiqui A.A., and Berk S.L. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis 33 (2001) 1040-1047
3. Pirisi M., Salvador E., Bisoffi Z., Gobbo M., Smirne C., Gigli C., et al. Unsuspected strongyloidiasis in hospitalized elderly patients with and without eosinophilia. Clin Microbiol Infect 12 (2006) 787-792
4. Loutfy M.R., Wilson M., Keystone J.S., and Kain K.C. Serology and eosinophil count in the diagnosis and management of strongyloidiasis in a non-endemic area. Am J Trop Med Hyg 66 (2002) 749-752
5. Schaffel R., Nucci M., Carvalho E., Braga M., Almeida L., Portugal R., et al. The value of an immunoenzymatic test (enzyme-linked immunosorbent assay) for the diagnosis of strongyloidiasis in patients immunosuppressed by hematologic malignancies. Am J Trop Med Hyg 65 (2001) 346-350
6. Boscolo M., Gobbo M., Mantovani W., Degani M., Anselmi M., Monteiro G.B., et al. Evaluation of an indirect immunofluorescence assay for strongyloidiasis as a tool for diagnosis and follow-up. Clin Vaccine Immunol 14 (2007) 129-133
7. Keiser P.B., and Nutman T.B. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev 17 (2004) 208-217
8. Page W.A., Dempsey K., and McCarthy J.S. Utility of serological follow-up of chronic strongyloidiasis after anthelminthic chemotherapy. Trans R Soc Trop Med Hyg 100 (2006) 1056-1062
9. Datry A., Hilmarsdottir I., Mayorga-Sagastume R., Lyagoubi M., Gaxotte P., Biligui S., et al. Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans R Soc Trop Med Hyg 88 (1994) 344-345
10. Gann P.H., Neva F.A., and Gam A.A. A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis 169 (1994) 1076-1079